Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), relating to its proposed sale to Gurnet Point Capital and Novo Holdings A/S. Under the terms of the agreement, PRTK shareholders are expected to receive $2.15 in cash per share they own and a contingent value right worth up to $0.85 per share.

Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc. (NASDAQ: KDNY), relating to its proposed sale to Novartis AG. Under the terms of the agreement, KDNY shareholders are expected to receive $40.00 in cash per share they own and contingent value rights worth up to $4.00 per share.

Reunion Neuroscience Inc.

Reunion Neuroscience Inc. (NASDAQ: REUN), relating to its proposed sale to affiliates of MPM BioImpact. Under the terms of the agreement, REUN shareholders will receive $1.12 in cash per share they own.

CIRCOR International, Inc.

CIRCOR International, Inc. (NYSE: CIR), relating to its proposed sale to funds managed by KKR. Under the terms of the agreement, CIR shareholders will receive $49.00 in cash per share they own.

CohBar, Inc.

CohBar, Inc. (NASDAQ: CWBR), relating to its proposed merger with Morphogenesis, Inc.

Greenhill & Co., Inc.

Greenhill & Co., Inc. (NYSE: GHL), relating to its proposed sale to Mizuho Financial Group, Inc. Under the terms of the agreement, GHL shareholders are expected to receive $15.00 in cash per share they own.

Syneos Health, Inc.

Syneos Health, Inc. (NASDAQ: SYNH), relating to its proposed sale to Elliott Investment Management, Patient Square Capital, and Veritas Capital. Under the terms of the agreement, SYNH shareholders are expected to receive $43.00 in cash per share they own.

PDC Energy, Inc.

PDC Energy, Inc. (NASDAQ: PDCE), relating to its proposed merger with Chevron Corp. Under the terms of the agreement, PDCE shareholders are expected to receive 0.4638 shares of Chevron per share they own.

Arlington Asset Investment Corp.

Arlington Asset Investment Corp. (NYSE: AAIC), relating to its proposed sale to Ellington Financial Inc. Under the terms of the agreement, AAIC shareholders will receive 0.3619 shares of Ellington and $0.09 in cash per share they own.